Literature DB >> 26704780

Rapid exacerbation of neuromyelitis optica after rituximab treatment.

Yongqiang Dai1, Tingting Lu1, Yuge Wang1, Ling Fang1, Rui Li1, Allan G Kermode2, Wei Qiu3.   

Abstract

Studies have shown the efficacy of immunosuppressants against neuromyelitis optica (NMO). Rituximab is recommended as an off-label prescription to treat refractory NMO. However, we describe two such patients who were suboptimally responsive to rituximab and whose symptoms worsened after treatment. Our cautionary cases highlight that in a small proportion of patients with refractory NMO, rituximab may either fail or induce rapid relapse of NMO. This suggests we need to consider new treatment strategies for refractory NMO.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Neuromyelitis optica; Relapse; Rituximab; Therapy

Mesh：

Substances：

Year:  2015        PMID： 26704780     DOI： 10.1016/j.jocn.2015.08.033

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN： 0967-5868            Impact factor:   1.961


  3 in total

Review 1.  Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Authors:  Bharath Wootla; Jens O Watzlawik; Nikolaos Stavropoulos; Nathan J Wittenberg; Harika Dasari; Murtada A Abdelrahim; John R Henley; Sang-Hyun Oh; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Opin Biol Ther       Date:  2016-03-10       Impact factor: 4.388

2.  Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.

Authors:  Philippe Cabre; M Mejdoubi; S Jeannin; H Merle; Y Plumelle; G Cavillon; D Smadja; R Marignier
Journal:  J Neurol       Date:  2018-02-17       Impact factor: 4.849

3.  Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.

Authors:  Jing Miao; Doreen E Aboagye; Boris Chulpayev; Lin Liu; Gary Ishkanian; Bangaruraju Kolanuvada; Dariush Alaie; Richard L Petrillo
Journal:  Am J Case Rep       Date:  2018-01-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.